T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA COMPLICATED WITH TOXOPLASMOSIS DURING MAINTENANCE THERAPY
DOI:
https://doi.org/10.15407/oncology.2025.04.259Keywords:
acute lymphoblastic leukemia, toxoplasmosis, infectious complications, maintenance therapy, immunosuppressionAbstract
Summary. Intensive chemotherapy remains the mainstay of treatment for acute lymphoblastic leukemia, but it results in significant immunosuppression, making infectious complications the main cause of morbidity and mortality. Although bacterial and fungal infections are most common, protozoal invasions, such as toxoplasmosis, are a rare but serious threat. This case report demonstrates the development of toxoplasmosis as a rare but critical complication in a patient with ALL during maintenance therapy. It emphasizes the need to include opportunistic protozoal infections in the differential diagnosis of worsening of the condition, particularly with the development of pancytopenia and fever, in immunocompromised patients, even in conditions of stable remission of the underlying disease.
References
Gomez S, Riccheri C, Deana C, et al. Infections deaths in acute lymphoblastic leukemia more frequent in high risk leukemia. JPIDS 2024; 13 (4): 28. https://doi.org/10.1093/jpids/piae093.073.
Carlesse F, Lopes de Sousa AV. Infections in children and adolescents with Acute Leukemia. EJC Paediatric Oncology 2024; 3: 100142. https://doi.org/10.1016/j.ejcped.2024.100142.
Kataria A, Lamin C, Badoule P, et al. Infectious complications in paediatric acute lymphoblastic leukemia during chemotherapy: A prospective observational study from Central India. Int J Life Sci Biotechnol Pharma Res 2025; 14 (5): 32–8. https://doi.org/10.69605/ijlbpr_14.5.2025.7.
Yin T, Han J, Hao J, et al. Clinical characteristics and risk factors of acute lymphoblastic leukemia in children with severe infection during maintenance treatment. Cancer Med 2023; 12 (19): 19372–82. https://doi.org/10.1002/cam4.6495.
Machado S, Oliveira LRG, Scalassara BM, et al. Acute lymphocytic leukemia associated with toxoplasmosis: case report. J Bras Patol Med Lab 2020; 56: 1–3. https://doi.org/10.5935/1676-2444.20200033.
Capela R, Moreira R, Lopes F. An overview of drug resistance in protozoal diseases. Int J Mol Sci 2019; 20 (22): 5748. https://doi.org/10.3390/ijms20225748.
Elsheikha HM, Marra CM, Zhu XQ. Epidemiology, pathophysiology, diagnosis, and management of cerebral toxoplasmosis. Clin Microbiol Rev. 2021; 34 (1): e00115–19. https://doi.org/10.1128/CMR.00115-19.
Aerts R, Mehra V, Groll AH, et al. Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022. Lancet Infect Dis 2024; 24 (5): e291–e306. https://doi.org/10.1016/S1473-3099(23)00495-4.
de Barros RAM, Torrecilhas AC, Marciano MAM, et al. Toxoplasmosis in human and animals around the world. diagnosis and perspectives in the one health approach. Acta Trop 2022; 231: 106432. https://doi.org/10.1016/j.actatropica.2022.106432.
